SQUO

In the status quo, pharmaceutical companies are using indiginous knowledge to great effect for pharmeceutical development with little renumeration for indiginous groups. The value of the pharmaceuticals developed from indiginous knowledge has been estimated to be 43 Billion dollars, with further economic value coming from drastically accelerated pharmeceutical development in plant derivatives, estimated to be ~4X faster.  


In particular, applying patent law to traditional knowledges is difficult as prior art docuemnted in the oral tradition is typically not considered, and the exact date of disclosure may be difficult to determine. (Newcity, 2009, p. 300). In a further fashion the patents prior art may have only been previously described in the context of an oral tradition, which is typically not legally admissable as prior art.(Newcity also, a couple pages later) In some jurisdictions the Oral tradition, such as those modeled after the European Patent Commission's approach, the oral tradition is only considered valid if previously recorded or if a 




A confounding factor is the sovereign claim to posession of IP derived from the biodiversity of its country, many of which have specific legislation regulating the development of commercial products from the biological resources of the nation. For example, the South African Biodiversity Act requires a permit for any bioprospecting with agreeements to share revenue derived from any bioprospecting or for any biological material to be exported for the same reason. (Mueller 2011, p. 396). The likely 

15 Tex. Wesleyan L. Rev. 357. Retrieved from http://www.lexisnexis.com/hottopics/lnacademic  http://www.lexisnexis.com/lnacui2api/api/version1/getDocCui?lni=54XS-PPW0-00CV-C017&csi=148395&hl=t&hv=t&hnsd=f&hns=t&hgn=t&oc=00240&perma=true
